Members |
targetComponentId |
zuclopenthixol 10 mg tablet |
Zuclopenthixol (as zuclopenthixol dihydrochloride) 10 mg oral tablet |
zuclopenthixol 2 mg tablet |
Zuclopenthixol (as zuclopenthixol dihydrochloride) 2 mg oral tablet |
zuclopenthixol 25 mg tablet |
Product containing precisely zuclopenthixol (as zuclopenthixol dihydrochloride) 25 milligram/1 each conventional release oral tablet (clinical drug) |
Product containing sodium chloride in oropharyngeal dose form (medicinal product form) |
Product containing sodium chloride in oromucosal dose form (medicinal product form) |
natriumchondroitinsulfat |
Chondroitin-containing product |
diatrizoatnatrium |
Product containing amidotrizoic acid (medicinal product) |
Product containing sodium diatrizoate in parenteral dose form (medicinal product form) |
Amidotrizoic acid-containing product in parenteral dose form |
Product containing sodium fluoride in oropharyngeal dose form (medicinal product form) |
Product containing sodium fluoride in oromucosal dose form (medicinal product form) |
natriumoxybat |
Product containing 4-hydroxybutyric acid (medicinal product) |
aminohippuratnatrium |
Para-aminohippuric acid-containing product |
Product containing sodium perborate in oropharyngeal dose form (medicinal product form) |
Sodium perborate-containing product in oromucosal dose form |
Product containing sodium phenylbutyrate in oral dose form (medicinal product form) |
Phenylbutyric acid only product in oral dose form |
Product containing sufentanil in sublingual dose form (medicinal product form) |
Sufentanil-containing product in oromucosal dose form |
testosteron til orofaryngal anvendelse |
Product containing testosterone in oromucosal dose form (medicinal product form) |
Product containing testosterone in subcutaneous dose form (medicinal product form) |
Testosterone-containing product in parenteral dose form |
Product containing tetracaine in oropharyngeal dose form (medicinal product form) |
Product containing tetracaine in oromucosal dose form (medicinal product form) |
Product containing triamcinolone in oropharyngeal dose form (medicinal product form) |
Triamcinolone-containing product in oromucosal dose form |
zinkundecenoat + undecensyre |
Product containing undecylenic acid (medicinal product) |
Product containing urate oxidase (medicinal product) |
Product containing enzyme (product) |
Product containing urate oxidase in parenteral dose form (medicinal product form) |
Product containing enzyme (product) |
Product inspector/grader NOS |
Product inspectors/graders |
Product inspector/grader NOS |
Product inspectors/graders |
Product inspector/packager NOS |
Product inspectors/packagers |
Product inspector/packager NOS |
Product inspectors/packagers |
præparater til orofaryngal anvendelse |
Product manufactured as oromucosal dose form (product) |
Production engineer NOS |
Production engineer |
Production engineer NOS |
Production engineer |
Production/materials clerk NOS |
Production/materials clerk |
Production/materials clerk NOS |
Production/materials clerk |
Productive cough NOS |
Productive cough |
Productive cough NOS |
Productive cough |
Professional sports occupation NOS |
Professional sport occupation (occupation) |
Professional sports occupation NOS |
Professional sport occupation (occupation) |
progesteron 100 mg, vaginalindlæg |
Progesterone 100 mg vaginal tablet |
progesteron 200 mg vagitorium |
Progesterone only product |
progesteron 400 mg vagitorium |
Progesterone only product |
progesteron 50 mg/ml olie |
Progesterone 50 mg/mL solution for injection |
Prognose, ikke nærmere specificeret |
Prognosis/outlook |
Prognosis/outlook NOS |
Prognosis/outlook |
Navlesnorsfremfald, ikke nærmere specificeret |
Prolapse of cord |
Navlesnorsfremfald, uspecificeret |
Prolapse of cord |
Navlesnorsfremfald med prænatalt problem |
Prolapse of cord |
fremfaldet arm med prænatalt problem |
Presentation of prolapsed arm of fetus |
Primær dystoci efter hindesprængning med prænatalt problem |
Prolonged artificial rupture of membranes |
forlænget 1. stadium med prænatalt problem |
Prolonged first stage of labor |
Forlænget fødselsproces, ikke nærmere specificeret |
Prolonged labor |
Prolonged labour NOS |
Prolonged labor |
Prolonged labour NOS |
Prolonged labor |
forlænget 2. stadium med prænatalt problem |
Prolonged second stage of labor |
filmovertrukken depotkapsel |
Prolonged-release oral capsule |
Prolonged-release intrauterine drug delivery system |
Prolonged-release intrauterine delivery system (dose form) |
transdermalt system |
Prolonged-release transdermal delivery system (dose form) |
Prolymphocytic leukemia |
Prolymphocytic leukemia |
promazin 12,5 mg/5 ml syrup |
Promazine 2.5 mg/mL oral solution |
Promazine hydrochloride 50mg/5mL conventional release oral syrup |
Product containing precisely promazine 10 milligram/1 milliliter conventional release oral solution (clinical drug) |
promazinhydrochlorid 50 mg/5 ml sukkerfri syrup |
Product containing precisely promazine 10 milligram/1 milliliter conventional release oral solution (clinical drug) |
Promegakaryocyte |
Promegakaryocyte |
promethazin 6,25 mg + dextromethorphan 15 mg 5 ml syrup til oral anvendelse |
Dextromethorphan hydrobromide 3 mg/mL and promethazine hydrochloride 1.25 mg/mL oral solution |
promethazinhydrochlorid 25 mg/5 ml syrup |
Product containing precisely promethazine hydrochloride 5 milligram/1 milliliter conventional release oral solution (clinical drug) |
Promethazine hydrochloride 50mg injection |
Product containing precisely promethazine hydrochloride 50 milligram/1 milliliter conventional release solution for injection (clinical drug) |
promethazinhydrochlorid 50 mg/ml injektionsvæske, opløsning, ampul |
Product containing precisely promethazine hydrochloride 50 milligram/1 milliliter conventional release solution for injection (clinical drug) |
promethazinhydrochlorid 6,25 mg/5 ml syrup |
Product containing precisely promethazine hydrochloride 1.25 milligram/1 milliliter conventional release oral solution (clinical drug) |
Prominent leg veins |
Prominent leg veins |
prominerende benvener - symptom |
Prominent leg veins |
Prominent veins (& [symptom]) |
Prominent veins |
Prominent veins (& [symptom]) |
Prominent veins |
prominerende vener - symptom |
Prominent veins |
Prominent veins NOS |
Prominent veins |
Prominent veins NOS |
Prominent veins |
Promotion of healing NOS |
Promotion of healing |
Promotion of healing NOS |
Promotion of healing |
Pronator quadratus flap |
Pronator quadratus muscle flap (substance) |
Prone body position for tube feeding of patient |
Lying with the chest of the body facing downward during delivery of enteral nutrition feeding. |
propafenonhydrochlorid 225 mg kapsel med modificeret udløsning |
Propafenone only product in oral dose form |
Propafenone hydrochloride 225mg prolonged-release oral capsule |
Propafenone only product in oral dose form |
propafenonhydrochlorid 325 mg kapsel med modificeret udløsning |
Propafenone only product in oral dose form |
Propafenone hydrochloride 325mg prolonged-release oral capsule |
Propafenone only product in oral dose form |
propafenonhydrochlorid 425 mg kapsel med modificeret udløsning |
Propafenone only product in oral dose form |
Propafenone hydrochloride 425mg prolonged-release oral capsule |
Propafenone only product in oral dose form |
Propamidine isethionate |
Product containing propamidine (medicinal product) |
propamidinisethionat 0,1 % øjendråber |
Product containing precisely propamidine isethionate 1 milligram/1 milliliter conventional release eye solution (clinical drug) |
allergi over for propamidin-isethionat |
Allergy to propamidine (finding) |
Proparacaine hydrochloride 0.5% solution |
Product containing precisely proxymetacaine hydrochloride 5 milligram/1 milliliter conventional release eye drops (clinical drug) |
Proparacaine hydrochloride 0.5%vv solution |
Product containing precisely proxymetacaine hydrochloride 5 milligram/1 milliliter conventional release eye drops (clinical drug) |
tilbøjelighed til bivirkninger af stof |
Propensity to adverse reaction |
Property sales rep. NOS |
Property sales representative |
Property sales representative NOS |
Property sales representative |
Property type |
This attribute is used to specify the type of inherent quality, function, disposition or process characteristic that is being observed or measured. Its values are abstract types of quality (length, odor, concentration) or abstract types of process characteristic (rate, speed, duration), and do not include qualities that are located (length of arm, odor of urine), or given a value (elevated concentration). |
Property/estate manager NOS |
Property/estate manager |
Property/estate manager NOS |
Property/estate manager |
Propess 10mg pessary |
Dinoprostone 10 mg prolonged-release vaginal pessary |
Prophylactic drug therapy NOS |
Administration of prophylactic drug or medicament (procedure) |
Prophylactic drug therapy NOS |
Administration of prophylactic drug or medicament (procedure) |
Propiomazine |
Product containing propiomazine (medicinal product) |
Propionibacterium lymphophilum |
Propionimicrobium lymphophilum (organism) |
Propioniferax innocus |
Propioniferax innocua (organism) |
Propiverine hydrochloride |
Product containing propiverine (medicinal product) |
Propofol 10mg/mL injection emulsion |
Propofol 10 mg/mL emulsion for injection |
Propofol 20mg/mL injection emulsion |
Product containing only propofol in parenteral dose form (medicinal product form) |
Propranolol hydrochloride |
Product containing propranolol (medicinal product) |
Propranolol hydrochloride + bendrofluazide |
Product containing bendroflumethiazide and propranolol (medicinal product) |